In Q1 of the fiscal year ending December 2026, revenue reached JPY 321.7 billion (11.5% YoY increase), operating income was JPY 158.8 billion (16.2% YoY increase), and quarterly profit was JPY 115.4 billion (18.7% YoY increase). The number of outstanding shares was 1,679,057,667 shares.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-04-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4519-20260424-01.pdf","jir_short_summary":"In Q1 of the fiscal year ending December 2026, revenue reached JPY 321.7 billion (11.5% YoY increase), operating income was JPY 158.8 billion (16.2% YoY increase), and quarterly profit was JPY 115.4 billion (18.7% YoY increase). The number of outstanding shares was 1,679,057,667 shares.","jir_summary":"### Performance Overview\nIn Q1 of the fiscal year ending December 2026, consolidated revenue was JPY 321.7 billion (11.5% YoY increase), operating income was JPY 158.8 billion (16.2% YoY increase), and quarterly profit stood at JPY 115.4 billion (18.7% YoY increase). Product sales amounted to JPY 291.6 billion (12.3% YoY increase), supported by growth in key and new products both domestically and internationally. Research and development expenses were JPY 41.9 billion (2.9% YoY increase), and selling, general and administrative expenses were JPY 24.9 billion (18.6% YoY increase), affected by higher corporate enterprise taxes. Core operating income was JPY 163.3 billion (17.1% YoY increase), and Core quarterly profit was JPY 118.6 billion (19.6% YoY increase).\n\n### Financial Position and Cash Flow Status\nAt the end of Q1, total assets stood at JPY 2.2651 trillion, total net assets were JPY 1.9077 trillion, resulting in a net asset ratio of 84.2%. Net cash decreased by JPY 129.6 billion from the previous period to JPY 850.1 billion. Cash flow from operating activities was JPY 122.0 billion (82.9% YoY increase), and free cash flow was JPY 112.2 billion (162.8% YoY increase). The dividend forecast remains unchanged at JPY 132 annually, down from JPY 272 in the prior period which included the 100th anniversary commemorative dividend.","jir_financial_highlights":"Revenue: JPY 321.7 billion (11.5% YoY increase)\nOperating Income: JPY 158.8 billion (16.2% YoY increase)\nQuarterly Profit: JPY 115.4 billion (18.7% YoY increase)\nNumber of Outstanding Shares (Common Stock): 1,679,057,667 shares (No change from previous period)\nDividend Forecast (Annual): JPY 132.00 (Decrease from previous period (JPY 272.00 in 2025))","jir_category":"","jir_hashtags":"#ChugaiPharmaceutical, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Revenue: JPY 321.7 billion (11.5% YoY increase)\nOperating Income: JPY 158.8 billion (16.2% YoY increase)\nQuarterly Profit: JPY 115.4 billion (18.7% YoY increase)","jir_meta_title":"Chugai Pharmaceutical Q1 2026 Earnings | Revenue JPY 321.7 Billion (+11.5% YoY)","jir_meta_description":"Chugai Pharmaceutical Co., Ltd. Q1 financial summary for the fiscal year ending December 2026. Reported revenue of JPY 321.7 billion (11.5% YoY increase), operating income of JPY 158.8 billion (16.2% YoY increase), and quarterly profit of JPY 115.4 billion (18.7% YoY increase).","jir_og_title":"Chugai Pharmaceutical Q1 2026 Earnings | Revenue JPY 321.7 Billion (+11.5% YoY)","jir_og_description":"Chugai Pharmaceutical\u2019s Q1 2026 financial results showing increased revenue and profit, with dividend forecast maintained at JPY 132.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"YoY Trends in Revenue\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q1\\\",\\\"2026 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (JPY 100 million)\\\",\\\"data\\\":[288459,321747],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"YoY Trends in Operating Income\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q1\\\",\\\"2026 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (JPY 100 million)\\\",\\\"data\\\":[136651,158765],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"quarter_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"YoY Trends in Quarterly Profit\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q1\\\",\\\"2026 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Profit (JPY 100 million)\\\",\\\"data\\\":[97234,115418],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Regional Composition of Product Sales in Q1 2026\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic Product Sales\\\",\\\"Overseas Product Sales\\\"],\\\"datasets\\\":[{\\\"data\\\":[111400,180100],\\\"backgroundColor\\\":[\\\"#76b7b2\\\",\\\"#59a14f\\\"]}]}}\"}, {\"jir_chart_id\": \"dividend_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Annual Dividend Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending Dec 2025\\\",\\\"Fiscal Year Ending Dec 2026 (Forecast)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Annual Dividend (JPY)\\\",\\\"data\\\":[272,132],\\\"backgroundColor\\\":\\\"#edc948\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-42516","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n